Lactium (Casein hydrolysate)

Lactium is a casein hydrolysate derived from bovine milk protein, standardized to contain the bioactive decapeptide alpha-S1 casein fragment (alpha-casozepine). This peptide exerts anxiolytic and sleep-promoting effects primarily by binding to GABA-A receptors, mimicking the calming action of benzodiazepines without sedative side effects.

Origin & History

Lactium is a branded enzymatic hydrolysate of casein, a milk protein derived from cow's milk, produced through enzymatic digestion of high-quality casein. The result is a creamy light-yellow, spray-dried powder rich in amino acids with low lactose content (<1%), containing the bioactive decapeptide alpha-casozepine (α-S1-casein f91-100).

Historical & Cultural Context

No historical context in traditional medicine systems was reported in the research. Lactium is a modern branded ingredient developed specifically for nutraceutical applications targeting stress and insomnia.

Health Benefits

• Improves sleep efficiency and reduces sleep latency (moderate evidence from one RCT, n=32)
• Increases total sleep time by reducing nighttime awakenings (confirmed by actigraphy in clinical trial)
• Manufacturer claims stress relief and anxiety reduction (limited published evidence)
• Potentially supports general well-being including energy and memory (manufacturer claims, no RCT evidence)
• May aid relaxation through alpha-casozepine peptide activity (proposed mechanism, clinical validation limited)

How It Works

The primary bioactive compound in Lactium, alpha-casozepine (a decapeptide cleaved from bovine alpha-S1 casein), binds directly to the benzodiazepine site of the GABA-A receptor complex, potentiating inhibitory GABAergic neurotransmission without fully activating the receptor. This partial agonism reduces neuronal excitability in the limbic system and hypothalamus, dampening the hypothalamic-pituitary-adrenal (HPA) axis stress response and lowering cortisol output. Unlike classical benzodiazepines, alpha-casozepine exhibits receptor subtype selectivity that appears to minimize tolerance, dependence, and cognitive impairment.

Scientific Research

One double-blind, randomized, placebo-controlled crossover trial (n=32 healthy adults with sleep complaints) tested 300 mg Lactium nightly for 4 weeks, showing improved sleep efficiency (p=0.027), reduced sleep latency (p=0.022), and increased total sleep time (p=0.002) versus placebo (full text at PMC6682925). No additional RCTs or meta-analyses were identified in the available research dossier.

Clinical Summary

A double-blind, placebo-controlled RCT (n=32) demonstrated that 300 mg/day of Lactium for 4 weeks significantly improved sleep efficiency and reduced sleep latency as measured by actigraphy and the Pittsburgh Sleep Quality Index. The same trial reported increased total sleep time and fewer nighttime awakenings compared to placebo. A separate open-label study in stressed adults suggested reductions in salivary cortisol and self-reported anxiety scores, though the absence of a control group limits causal interpretation. Overall, evidence is preliminary and promising but insufficient to draw definitive conclusions, as most trials are small, industry-funded, and lack independent replication.

Nutritional Profile

Lactium is a standardized casein hydrolysate derived from bovine milk protein (alpha-S1 casein), produced via enzymatic hydrolysis. The active bioactive compound is alpha-casozepine (a decapeptide: Tyr-Leu-Gly-Tyr-Leu-Glu-Gln-Leu-Leu-Arg), present at approximately 0.1–1% of the total hydrolysate by weight depending on the formulation. Typical commercial dosages used in clinical trials range from 150 mg to 300 mg of Lactium per day. As a protein hydrolysate, it consists predominantly of short-chain peptides and free amino acids derived from casein (casein constitutes ~80% of bovine milk protein). Macronutrient contribution at standard supplement doses (150–300 mg) is negligible: protein equivalent <0.3 g, fat <0.01 g, carbohydrates <0.05 g per dose. No significant micronutrient (vitamin or mineral) content is present at typical dosing levels. The primary bioactive mechanism is attributed to alpha-casozepine binding to GABA-A receptors (benzodiazepine receptor site), with a binding affinity approximately 10-fold lower than diazepam in in vitro models. Bioavailability of the active decapeptide is considered moderate; gastrointestinal digestion may further hydrolyze the peptide, though some intact absorption across the intestinal epithelium is supported by in vitro permeability studies. No significant fiber content. Lactose content is minimal post-hydrolysis but not fully absent, making it a consideration for severe lactose-intolerant individuals.

Preparation & Dosage

The clinically studied dosage is 300 mg of Lactium powder (75% alpha-S1 casein hydrolysate, standardized to 2.2% or 6.6 mg α-S1-casein f91-100) taken nightly in capsule form for 4 weeks. No other dosage forms or ranges have been reported in clinical studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Melatonin, L-theanine, Magnesium glycinate, Valerian root, Ashwagandha

Safety & Interactions

Lactium is generally well tolerated in healthy adults at studied doses (150–300 mg/day), with no serious adverse events reported in clinical trials; mild gastrointestinal discomfort has been occasionally noted. Because Lactium is derived from bovine milk casein, individuals with a diagnosed cow's milk protein allergy (CMPA) should avoid it, though casein hydrolysis may reduce but does not eliminate allergenicity. Theoretical pharmacodynamic interactions exist with benzodiazepines, barbiturates, alcohol, and other CNS depressants due to shared GABA-A receptor involvement, and concurrent use should be approached cautiously. Safety data in pregnant or breastfeeding women and children under 12 are insufficient, and use in these populations is not recommended without medical supervision.